Testing for WEB-711: https://llsoperations.atlassian.net/browse/WEB-711

We're accepting and reviewing partnering inquiries now.

1. Download and complete the TAP Inquiry Form 

2. Send the completed inquiry form and non-confidential presentation to Dr. Jun Xu, Executive Director - TAP Lead, Therapy Acceleration Program via email at [email protected] 

The approval process takes into account strategy, opportunities, and the potential for success. 

NEED MORE INFO? Download this presentation (PDF) and one-page information sheet (PDF) to learn more. 

Powerful Value-Added Benefits as Part of TAP Partnership

It starts with an equity investment in your company, but there are many other powerful TAP value-added benefits that companies can enjoy as part of the partnership.  

Currently, there are more than twenty LLS-supported assets in clinical development, including four ongoing or planned registration-enabling studies. But companies in the TAP portfolio have a higher probability of partnering with other companies or financial institutions. Being selected for the TAP Portfolio can have major benefits for companies— (aside from helping to cure blood cancers, of course.) 

Strategy and Criteria

When determining who qualifies for inclusion in the TAP Portfolio, we consider many factors:

• Existing and emerging populations with high unmet needs
• Gaps in current and emerging treatment landscape
• Innovative science, first-in-class assets
• First-in-hematology/oncology and registration trials
• Strong intellectual property, management, and finances

Investment Models and Due Diligence Process

Investment models are focused on equity transactions to enable fast progression and provide greater ROI potential to the LLS mission. When it comes to investment models, there are two paths for TAP to co-invest with other investors or syndicate groups.

Strategic

• Range of Investment: $2 Million to $10 Million

• Presentation to TAP Committee

• Typically, 3 6 months to reach TAP Committee

Opportunistic

• Target Investment: $500,000

• LLS TAP team briefs TAP Committee Chair

• Transaction completion in 1 3 months

The rigorous TAP due diligence process includes five stages, including utilizing external experts (TAP Advisory Council) to assist with evaluation

TAP Adds Value to Biotech Companies

Why do companies want to be part of TAP? Because of active collaboration with us, TAP portfolio companies benefit from LLSs deep cancer insight, key opinion leader (KOL) and clinical network, drug development, and business expertise. Specifically, TAP portfolio companies benefit from LLS blood cancer insight, including:

• Unique scientific, clinical, and drug development expertise

• Scientific due diligence and investment credibility enabling biotech companies to raise additional funds

• Patient access services to enable understanding of patient needs

• Immediate access to extensive KOL network

• Pharmaceutical, biotech, and research institution partner connections

• Regulatory insight through LLS initiatives

• Introduction to LLS patient services, including the LLS Clinical Trial Support Center and the Information Resource Center

What's more, TAPs record of success provides scientific and investment credibility, plus coveted visibility that enables companies to raise additional funds. Hear what the SVP of Corporate & Business Development of Stemline Therapeutics has to say about TAP and the value created for his company beyond the funding amount. LLS TAP partnered with Stemline in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

LLS Therapy Acceleration Program® (TAP) Supported Stemline’s Key Clinical Studies in BPDCN 

"Funding from leaders like LLS TAP helps fuel the progress of our clinical development program, bringing next-generation treatments that much closer to patients. Were particularly excited to be working with LLS TAP because it gives us access to their deep knowledge of blood cancer and their network of patients and drug development experts"

- Rachel Haurwitz, Ph.D., Co-Founder, President and Chief Executive Officer of Caribou Biosciences

LLS Therapy Acceleration Program® (TAP) Supported Forty Seven’s Key Clinical Studies in NHL and MDS